VitriVax is a technology company.
VitriVax has raised $17.0M across 1 funding round.
VitriVax has raised $17.0M in total across 1 funding round.
VitriVax has raised $17.0M in total across 1 funding round.
VitriVax's investors include Adjuvant Capital, Charles Petty.
VitriVax is a biotechnology company developing the ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) platform to create thermostable, single-dose vaccines that eliminate cold chain requirements and improve global accessibility.[1][2][3][6] It targets challenges like vaccine instability during transport and the need for multiple doses, serving public health needs in remote areas, emergencies, and military applications through scalable manufacturing with GRAS ingredients.[1][3] The company has strong growth momentum, raising $17.25M in Series B financing (2024), securing a $9.9M grant for clinical manufacturing scale-up (2025), and receiving awards like a $29M DoD contract, $5M Gates Foundation grant, and others totaling significant non-dilutive funding.[3]
VitriVax emerged as a spinout from the University of Colorado Boulder, based on research in the labs of Bob Garcea (Molecular, Cellular & Developmental Biology) and Ted W. Randolph (Chemical and Biological Engineering), who developed the foundational stabilization and delivery platform.[3] Headquartered in Boulder, Colorado, the company was formed to commercialize this technology, with early momentum from CU Boulder's startup ecosystem, including state accelerator programs (2017) and Buff Venture Fund investments (2023).[3] Key leadership includes Rom Colindres as CEO, guiding it through pivotal funding rounds and grants that accelerated development of products like temperature-stable rabies vaccines.[3][5]
VitriVax rides the trend of global vaccine equity, addressing cold chain limitations that hinder 50%+ of doses in low-resource settings amid rising demands for pandemic preparedness and endemic disease control.[1][3] Timing aligns with post-COVID lessons on distribution bottlenecks and military/emergency needs, amplified by climate impacts on logistics.[1][3] Market forces like increasing biopharma outsourcing for formulations and non-dilutive funding for public health innovations favor its platform, positioning it to influence ecosystems by enabling partners to reach underserved populations and reduce waste.[2][3][4]
VitriVax is primed for clinical advancement, with 2025 grants funding scale-up of manufacturing and preclinical rabies vaccines, potentially leading to first human trials soon.[3][5] Trends like mRNA stabilization demands and single-dose mandates will shape its path, evolving its influence from niche innovator to key enabler in global immunization networks. As barriers to vaccination fall, VitriVax stands to redefine accessibility, echoing its mission to save lives through thermostable tech.[1][6]
VitriVax has raised $17.0M across 1 funding round. Most recently, it raised $17.0M Series B in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $17.0M Series B | Adjuvant Capital, Charles Petty |